[O3-3] SARS2-6

[O3-3-10] Characteristics and in vivo antiviral effects of anti-SARS-CoV-2 monobodies

*Kazuhiro Matsuoka¹, Yu Adachi², Keisuke Tonouchi², Taishi Kondo³, Shun Umemoto³, Takako Miyabe-Nishiwaki⁴, Akihisa Kaneko⁴, Yuto Sawada⁴, Ayaka Washizaki⁴, Saya Moriyama², Ryutaro Kotaki², Mai Kubota¹, Yoshihiro Nakata^1,5, Hirotaka Ode¹, Hirofumi Akari⁴, Hiroshi Murakami³, Yoshimasa Takahashi², Yasumasa Iwatani^1,5 (1. Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, JAPAN, 2. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, JAPAN, 3. Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, JAPAN, 4. Center for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, JAPAN, 5. Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, JAPAN)